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DNA polymerase ι is acetylated in 
response to sN2 alkylating agents
Justyna McIntyre1, Aleksandra sobolewska1, Mikolaj Fedorowicz1, Mary p. McLenigan2, 
Matylda Macias3, Roger Woodgate2 & ewa Sledziewska-Gojska1
DNA polymerase iota (polι) belongs to the Y-family of DNA polymerases that are involved in DNA 
damage tolerance through their role in translesion DNA synthesis. Like all other Y-family polymerases, 
polι interacts with proliferating cell nuclear antigen (PCNA), Rev1, ubiquitin and ubiquitinated-PCNA 
and is also ubiquitinated itself. Here, we report that Polι also interacts with the p300 acetyltransferase 
and is acetylated. The primary acetylation site is K550, located in the Rev1-interacting region. However, 
K550 amino acid substitutions have no effect on Polι’s ability to interact with Rev1. Interestingly, we 
find that acetylation of Polι significantly and specifically increases in response to SN2 alkylating agents 
and to a lower extent to sN1 alkylating and oxidative agents. As we have not observed acetylation 
of Polι’s closest paralogue, DNA polymerase eta (Polη), with which Polι shares many functional 
similarities, we believe that this modification might exclusively regulate yet to be determined, and 
separate function(s) of Polι.
The transfer of an acetyl group from acetyl coenzyme A to a specific site on a protein is one of the major 
posttranslational modifications and one of many that modify lysine residues1,2. Lysine acetylation was first dis-
covered in histones and its significance in transcription control has been demonstrated3,4. Besides transcrip-
tion, acetylation regulates many other cellular processes including the cell cycle, proliferation, apoptosis, DNA 
recombination, stress response and DNA repair5–7. Lysine acetylation can have a profound and diverse impact 
on modified proteins as it can influence protein stability, localization, enzymatic activity, as well as DNA and 
protein binding8–11. Acetylation is a dynamic modification catalyzed by acetyltransferases that can be reversed 
by deacetylases. The lysine acetyltransferases (KATs) are grouped in three major families and one of them, p300/
CREB-binding protein (CBP), consists of just two members, p300 and CBP12.
Mammalian p300 and CBP are paralogs sharing 86% amino acid identity in their aminotransferase domain 
and while they are conserved in metazoans, they do not have detectable sequence homology with other KATs12,13. 
The enzymes possess a bromodomain that recognizes acetylated substrates and multiple other non-catalytic 
domains involved in protein binding14. Additionally, a non-canonical, but functional RING domain, connects 
the enzymes with ubiquitination processes15,16. p300/CBP interact with over 400 proteins and act as network hubs 
in different cellular pathways, often in complexes controlling transcriptional activation17. Defects in these acet-
yltransferases have been linked to human diseases, including several types of cancer, heart malfunction, diabetes 
mellitus, as well as Rubinstein-Taybi syndrome, which is characterized by developmental abnormalities and can-
cer predisposition17,18. On the other hand, due to the fact that p300/CBP are involved in the regulation of many 
tumor-relevant proteins including p53, c-myc, or BRCA1, many therapeutic strategies targeting p300/CBP are 
under investigation [reviewed in19–22]. Despite the high homology between p300 and CBP, there is accumulating 
evidence to suggest that CBP and p300 are not fully redundant but, due to differential association with other pro-
teins, or diversity in their substrate specificity, also have unique roles in vivo [reviewed in18].
p300/CBP-directed lysine acetylation seems to play an important and diverse role in DNA replication and 
the DNA damage response. The p300/CBP-acetylated proteins are engaged in DNA damage recognition, signa-
ling and most DNA repair pathways [23,24, reviewed in5]. However, until recently, there is little indication for the 
involvement of p300/CBP in the regulation of DNA damage tolerance mechanisms. Our previous report was the 
first to suggest such a possibility25. We proposed that p300 acetyltransferase inhibition influences polyubiquitina-
tion of DNA polymerase iota (Polι), a non-canonical polymerase involved in DNA translesion synthesis (TLS).
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Even though TLS and other DNA damage tolerance processes do not actually repair DNA lesions, they play a 
crucial role in cell survival and genomic stability maintenance [reviewed in26]. They are particularly important in 
dividing cells, as DNA synthesis by replicative polymerases is stalled by lesions in the template DNA. The threat 
of a replication block may be circumvented by employing TLS polymerases, which are able to incorporate a 
nucleotide opposite the normally replication-blocking lesion27. Depending on the lesion and the TLS polymerase 
employed, TLS can be accurate, or highly error-prone28.
DNA polymerases (Pols) eta (η), iota (ι), kappa (κ) and Rev1 belong to the Y-family of DNA polymerases 
that are best known for their TLS activity29, which is credited to their flexible and capacious active site, thereby 
allowing them to accommodate damaged nucleotides. Polη, a flagship member of the Y-family DNA polymerases, 
is able to correctly bypass a thymine-thymine cyclobutane pyrimidine dimer (CPD), which is the most common 
mutagenic UV-light induced DNA lesion. Accordingly, the lack of Polη in XPV cells makes them sensitive to 
UV-radiation. It was shown that in the absence of Polη, its closest paralogue, Polι, bypasses UV induced photo-
products and functions in a manner that delays the onset of skin cancer in mice30,31. Both Polη and Polι can copy 
a template with the most common oxidative DNA lesion, 8-oxoG. However, Polι does so by utilizing its ability 
for Hoogsteen pairing32,33. Additionally, both of the polymerases can, to some extent, participate in the bypass of 
lesions induced by methylating agents34. In vitro experiments have shown that Polι is capable of bypassing many 
other DNA lesions33,35–38, while in vivo a Polι deficiency has been suggested to sensitize cells to oxidative DNA 
damage39 and cause UV-induced mesenchymal tumorigenesis40.
As a consequence of a spacious active site, Y-family polymerases are more liberal than classical replicases in 
the selection of an incoming nucleotide, which together with a lack of proofreading activity, results in frequent 
mistakes when they synthesize DNA on an undamaged template41. Polι is the most mutagenic among all known 
human polymerases and its fidelity is strictly template-dependent42,43.
The recruitment of Y-family polymerases to the replication fork occurs as a result of complex regulation where 
protein posttranslational modifications and protein interactions play fundamental roles. All Y-family polymer-
ases can interact through their dedicated domains with the replication processivity factor, PCNA. These inter-
actions are additionally strengthened after DNA damage-induced PCNA monoubiquitination, as all Y-family 
polymerases are equipped with one or two, ubiquitin binding domains (UBMs or UBZs)44,45. Rev1 protein repre-
sents another interaction platform coordinating targeting of TLS polymerases to the blocked replication fork. In 
addition to protein-protein interactions, posttranslational modifications of Y-family polymerases seem to provide 
more specific instructions for their participation in TLS2. Consequently, it was shown that the modification status 
of Polη dramatically changes in response to DNA damage46. UV irradiation produces CPD dimers, the cognate 
substrate of Polη, and results in changes to the ubiquitination, phosphorylation and GlcNAcylation status of the 
TLS polymerase, which subsequently affects its recruitment to a stalled replication fork, CPD bypass and removal 
from DNA after TLS, respectively46–51. The modification of Polι caused by DNA damage has not been reported 
so far. In contrast to Polη, the monoubiquitination status of Polι does not change in response to DNA damaging 
agents, but the extent of polyubiquitination increases significantly after treatment with 1,4-naphthoquinones25. 
We have previously presented evidence that menadione-induced Polι polyubiquitination does not occur due to 
oxidative damage, but rather the inhibition of p300/CBP acetyltransferase activity25.
In the current work, we have shown that Polι is acetylated by the p300/CBP acetyltransferases and that this 
response is especially strong in cells treated with the SN2 alkylating agents, methyl methanesulphonate (MMS) 
and dimethyl sulfate (DMS), but not other DNA damaging treatments. We have identified the key protein interac-
tions responsible for this modification and pinpointed the primary residue in Polι that is acetylated. Interestingly, 
while we found that the response to SN2 alkylating agents targets Polι for acetylation, the same is not true for its 
closest paralogue, Polη, suggesting a differentiation of cellular functions of these TLS polymerases. The possible 
consequences of acetylation on the cellular function(s) of Polι are discussed.
Results
p300 Interacts with Polι. Our previous results suggested a link between Polι polyubiquitination and inhi-
bition of the lysine acetyltransferase activity p30025, a large, multi-domain protein (Fig. 1a) influencing multiple 
processes in the cell [reviewed in12]. To further corroborate the relationship between Polι and p300, we initially 
investigated whether p300 physically interacts with Polι. We confirmed the interaction by performing FLAG 
co-immunoprecipitation assays in HEK293T cells transiently transfected with FLAG-Polι and a p300-c-myc 
expression vector (Fig. 1b). Additionally, we have also demonstrated the interaction between endogenous p300 
and Polι proteins by performing a proximity ligation assay (PLA) (Fig. 1b).
Because p300 can both acetylate and ubiquitinate substrates16, we next examined whether the RING ubiquitin 
ligase domain, which is present in the p300 protein, or the HAT domain, which is responsible for the acetyltrans-
ferase activity of p300, is required for the interaction with Polι. The catalytic regions of p300 form a compact 
module in which the RING domain is juxtaposed with the HAT domain. We performed immunoprecipitation 
experiments with transiently transfected HEK293T cells using either of the two HA-tagged p300 deletion con-
structs and FLAG-tagged Polι. p300ΔC (amino acids 1–1287) lacking the HAT domain failed to interact with 
Polι, while p300ΔN (amino acids 1046–2414) interacted strongly with the protein, indicating that C-terminal 
half of the p300 protein, including the HAT domain, is required for binding to Polι (Fig. 1c).
To further map the interaction between Polι and p300 and identify a region in Polι necessary for an inter-
action with the p300 protein, we generated a series of Polι deletion constructs lacking domains involved in 
protein-protein interactions including the ubiquitin binding motifs UBM1 and UBM2, the Rev1-interacting 
region (RIR) and the PCNA interacting peptide (PIP) (Fig. 2a). We used the HA-immunoprecipitation assay in 
HEK293T cells transiently transfected with HA-tagged p300ΔN and full-length, or truncated versions of Polι. 
As shown in Fig. 2b, HA-p300ΔN interacted with all of the Polι constructs lacking the known protein interacting 
domains, which suggests that the Polι catalytic domain located at the N-terminus of the protein is sufficient for 
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Figure 1. Mapping the region of p300 that interacts with Polι. (a) Schematic representation of p300 deletion 
constructs. The colorful block represents some of the important domains in p300: Bd - bromodomain, 
RING - non-canonical RING domain characteristic for ubiquitin ligases, PHD - plant homodomain, HAT - 
acetyltransferase catalytic domain, AIL -autoinhibitory loop. The amino acid location of the various domains 
are indicated above the block scheme. Constructs used are shown below. (b) Interaction between Polι and p300. 
Left panel shows the results of immunoprecipitation assays (IP) performed with anti-FLAG resins incubated 
with extracts (E) from cells co-expressing p300-c-myc and FLAG-Polι or p300-c-myc and empty FLAG vector 
as a negative control. Right panel shows the results of the proximity ligation assay (PLA), signal (red) provides 
evidence that endogenous Polι and p300 are close together in the cell, actin cytoskeleton is shown in green 
(Alexa488 Phalloidin staining), nucleus in blue (Hoechst staining). Scale bar is 10 µm. (c) Immunoprecipitation 
assays (IP) were performed with anti-FLAG resins that were incubated with extracts (E) from cells expressing 
FLAG-Polι or FLAG empty vector as a negative control and either of HA-tagged p300 deletion constructs 
p300ΔN or p300ΔC.
Figure 2. Mapping the region of Polι that interacts with p300. (a) Schematic representation of Polι with 
indicated domains, and Polι deletion constructs. (b) Immunoprecipitation assays were performed with 
10μl of anti-HA resins that were incubated with equal amounts of extracts from cells co-expressing HA-
p300ΔN and full-length FLAG-Polι or FLAG-Polι with deletions of various protein interacting domains. 
(c) Immunoprecipitation assays were performed with 10μl of anti-HA resins that were incubated with equal 
amounts of extracts from cells co-expressing HA-p300ΔN and full-length FLAG-Polι or FLAG-Polι lacking 
the N-terminal catalytic domain (IP- immunoprecipitation). In (b,c) the input controls contain 20μg or 10μg of 
protein extracts, respectively.
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the interaction with p300. To verify this hypothesis, we tested the interaction of HA-p300ΔN with Polι lacking 
the catalytic domain, but possessing all known protein-interacting regions (409–715aa). The recombinant Polι 
protein lacking its N-terminus did not interact with p300, implying that the presence of the catalytic domain of 
Polι is required for its interaction with the p300 protein (Fig. 2c).
polι is Acetylated in vivo and in vitro. Our current studies show that Polι directly binds the C-terminal 
half of p300 protein including the HAT domain. This interaction prompted us to test whether Polι is acetylated 
by p300 in vivo and in vitro. As demonstrated in Fig. 3a, acetylation of FLAG-tagged Polι was clearly detected 
in an immunoprecipitated (IP) complex using anti-FLAG resins, when cells co-expressing FLAG-Polι and 
p300-c-myc were pre-treated for 24 h with a deacetylation inhibitor (DKAc) cocktail, in contrast to cells treated 
with DMSO. To verify whether p300 is responsible for Polι acetylation, we co-transfected FLAG-Polι with either 
full-length wild-type p300 protein, or a variant with a D1399Y mutation that reduces acetyltransferase activ-
ity52. The acetylation of Polι decreased dramatically when co-expressed with the p300 D1399Y mutant with the 
acetyltransferase-deficiency, suggesting that Polι can be acetylated by p300 (Fig. 3b). In addition, we proved that 
Polι can be acetylated by p300 by performing in vitro experiments, in which full-length p300 was incubated with 
a purified His-tagged Polι protein and acetyl coenzyme A (Fig. 3c).
Identification of Polι Acetylation sites. To further explore acetylation of Polι, we performed a series of 
mass spectrometry analyses to identify residues of Polι that are acetylated in vivo and in in vitro. We initially used 
anti-FLAG resins to purify FLAG-tagged Polι from HEK293T transiently transfected with the FLAG-Polι plas-
mid. These cells were then incubated with, or without, DKAc inhibitors for 24 hours (Fig. 4a) before the purified 
proteins were run on an SDS-PAGE gel and analyzed by mass spectrometry. Additionally, small amounts of the 
purified proteins were evaluated by western blot using antibodies against acetylated lysines and Polι. Compared 
to Polι isolated from untreated cells, we observed a faint acetylation signal from FLAG-Polι purified from cells 
Figure 3. In vivo and in vitro acetylation of Polι by p300. (a) Immunoprecipitation assay of extracts from 
HEK293T cells co-transfected with FLAG-Polι and wild-type p300-c-myc. As indicated, prior to harvesting, 
cells were treated either with DMSO or with deacetylase inhibitor (DKAc) cocktail. (b) Immunoprecipitation 
assay used extracts from HEK293T cells co-transfected with FLAG-Polι and wild-type p300-c-myc, or FLAG-
Polι and p300 containing the D1399Y mutation that abolishes the acetyltransferase activity of p300. 24hrs prior 
to harvesting, cells were treated with DKAc inhibitor. In panels (a,b), Polι acetylation was verified by western 
blot using antibodies against acetylated lysines (KAc). Polι was visualized using polyclonal rabbit antibodies 
against a C-terminal fragment of Polι. (c) In vitro acetylation of recombinant His-tagged Polι by p300. The 
reaction products were resolved by SDS-PAGE and analyzed by western blot using antibodies against KAc and 
against Polι.
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treated with the DKAc inhibitor cocktail. In agreement with the western blot results, mass spectrometry analysis 
did not reveal any acetylated residues in untreated cells, whereas K550 was identified as the main acetylation site 
when cells were treated with DKAc inhibitors. In the Polι protein that was acetylated in vitro, we identified four 
acetylated lysines: K138, K440, K550 and K715 (Fig. S1). K550 is located in the RIR domain that is responsible 
for Polι’s interaction with Rev1, and was the only residue identified in both approaches. To determine if it is 
the primary site of acetylation, we co-transfected human HEK293T cells with a plasmid expressing p300 and a 
recombinant plasmid carrying wild-type FLAG-tagged Polι, or one containing a K550R substitution. Transfected 
cells were treated with DKAc inhibitor cocktail. Proteins pulled-down with anti-FLAG resin were then probed 
with antibodies against acetylated lysines. In the K550R mutant, the acetylation signal was significantly reduced 
(Fig. 4b), but still observable, thereby confirming that K550 is the primary acetylation site, but also suggesting the 
existence of alternate acetylation site(s) in vivo.
Interaction of Acetylated Polι with Rev1. Our observation that K550, which is located in the RIR 
domain, is the major acetylation site in Polι protein prompted us to check the role of the K550 residue itself and its 
acetylated form in the interaction of Polι with Rev1. Using anti-HA resins, we performed immunoprecipitation 
assays on extracts from HEK293T transiently transfected with plasmids encoding HA-tagged full-length Rev1 
and either wild-type FLAG-Polι, or a variant carrying a single point mutation at K550. K549 is adjacent to K550 
and it is known that if the primary residue is unavailable for posttranslational modification, the neighboring sites 
could be modified46. To determine if K549 might compensate for K550 if it is unavailable for acetylation, we also 
tested whether a double point mutation of K549 and K550 influences Polι’s interaction with Rev1. Initially, we 
tested lysine-to-arginine (K → R) mutants. Both, the single and double mutant of Polι maintained the interaction 
with Rev1 (Fig. 5a). To study the effect of the acetylation on the Polι-Rev1 interaction, we replaced the lysine res-
idues with glutamine, since previous studies have suggested that glutamine substitutions simulate acetylation53,54. 
Immunoprecipitation experiments with K → Q Polι mutants indicate that there is no effect on Polι’s ability to 
interact with Rev1 (Fig. 5b). As a control for these experiments, we used an F546A/F547A Polι mutant, that has 
been shown to abolish the interaction between Polι and Rev155. Together, our results suggest that K → R muta-
tions, which simulate an unmodified state, or K → Q mutations, which mimic acetylation, do not significantly 
change the interaction between Polι with Rev1.
polι Acetylation in Response to a Variety of DNA Damaging Agents. The Polι acetylation observed 
in the previous experiments was mostly detected in cells overexpressing the p300 protein. To determine the physi-
ological conditions under which Polι is acetylated we tested acetylation of the ectopically expressed FLAG-Polι in 
cells with native levels of p300, after treatment with a variety of DNA damaging agents. We investigated the influ-
ence of UV irradiation, which induces cyclobutane pyrimidine dimers and other photoproducts; MMS, a source 
of alkylating damage; zeocin stimulating DNA double strand breaks; hydrogen peroxide, causing DNA oxida-
tive lesions and two DNA crosslinking agents, used in chemotherapy, mitomycin C and cisplatin. Additionally, 
we have also tested whether hydroxyurea, which blocks replication fork progression due to decreased dNTPs 
production, has any influence on the acetylation status of Polι. As shown in Fig. 6a, exposure of cells to most 
of the DNA damaging agents and hydroxyurea did not result in significant Polι acetylation. In contrast, MMS 
treatment substantially induced Polι acetylation. We also observed a weak Polι acetylation signal in hydrogen 
peroxide treated cells. To further analyze the phenomenon of Polι acetylation in response to MMS and hydrogen 
peroxide, we tested whether other alkylating and oxidizing agents were also able to induce Polι acetylation. We 
exposed HEK293T cells to increasing concentrations of hydrogen peroxide and potassium bromate, which is 
known to cause DNA oxidative lesions (Fig. 6b). Both oxidative agents, at higher doses, caused some acetylation 
of Polι. In comparison to MMS, we investigated the influence of other alkylating agents, EMS and MNNG, on Polι 
Figure 4. Identification of acetylation sites in Polι. (a) Coomassie Brilliant Blue-stained gel (left panel) of 
FLAG-tagged Polι purified from HEK293T cells transfected with the FLAG-Polι plasmid and treated, or 
untreated, with DKAc inhibitor cocktail as indicated. Polι acetylation of purified Polι was visualized by western 
blot (right panel) using monoclonal antibodies against acetylated lysines (KAc). Polι was visualized using 
polyclonal rabbit antibodies against a C-terminal fragment of Polι. (b) Effect of the K550R substitution on Polι 
acetylation. Western blot using monoclonal antibodies against acetylated lysines. Polι was visualized using 
polyclonal rabbit antibodies against a C-terminal fragment of Polι.
6Scientific RepoRts |          (2019) 9:4789  | https://doi.org/10.1038/s41598-019-41249-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
acetylation (Fig. 6c). Both alkylating agents caused some acetylation of Polι that was much weaker than MMS. 
Since alkylation by MMS proceeds via second-order nucleophilic substitution (SN2) and MNNG is an SN1 alkyl-
ating agent, we examined acetylation of Polι with DMS, another SN2 alkylating agent. Interestingly both MMS and 
DMS induced a much higher acetylation level than EMS and MNNG. It is known that compared to MMS, much 
lower concentrations of DMS induce the same amount of alkylation damage56, which might explain the difference 
in the strength of the acetylation signal when using equimolar amount of MMS and DMS.
Characterization of MMS-induced Polι acetylation. To further corroborate MMS-induced Polι acetyl-
ation, we used mass spectrometry analysis to identify Polι acetylation sites in cells exposed to MMS. HEK293T 
cells transiently transfected with the FLAG-Polι plasmid were exposed to 200 μM MMS for 1 h. In a control 
sample from cells not treated with MMS, K550 was again the only acetylated residue. The analysis of Polι protein 
isolated from MMS-exposed cells also revealed acetylation of K550 and an additional three other lysine residues; 
K440, K446 and K530 (Fig. S2). Next, by using the K550R mutant, we examined whether K550 is an important 
site for MMS-induced Polι acetylation. Indeed, MMS-stimulated Polι acetylation was drastically reduced when 
K550 was unavailable for modification (Fig. 7a). We conclude that K550 is, in general, the main Polι acetylation 
site after MMS treatment. To test the in vivo properties of the acetylated and unacetylated protein, we examined 
if Polι variants with K550R and K550Q substitutions could accumulate in DNA replication foci similar to the 
wild-type protein. Our results show that mutations that either block posttranslational modification(s) at K550 
(K550R) or mimic its acetylation (K550Q), do not alter the accumulation of Polι into “replication factories” 
(Fig. 7b) suggesting that acetylation functions in fine tuning, rather than in the general regulation of Polι’s cel-
lular activities. We also speculate that, since the main acetylation site is located outside the catalytic domain of 
Polι, it is unlikely to directly affect Polι’s enzymatic activities. We do not however, exclude that it might indirectly 
Figure 5. Effect of mutating Polι K550 residue and its interaction with Rev1. (a) Immunoprecipitation 
of Rev1 and wild-type Polι, or Polι K550 mutants. Immunoprecipitation assays were performed with 
HA-tagged full-length Rev1 immobilized on anti-HA resins that were incubated with extracts from cells 
expressing FLAG-tagged wild-type Polι, or Polι carrying single K550R, or double K549R/K550R mutations. 
(b) Immunoprecipitation of Rev1 and wild-type Polι, or Polι mutants mimicking K550 acetylation. 
Immunoprecipitation assays were performed with HA-tagged full-length Rev1 immobilized on anti-HA resins 
that were incubated with extracts from cells expressing FLAG-tagged wild-type Polι, or Polι carrying single 
K550Q, or double K549Q/K550Q mutations. As a control, the lack of interaction between Rev1 and Polι F546A/
F547A is shown. E-extract, IP- immunoprecipitation.
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Figure 6. Effect of DNA-damaging agents on Polι acetylation in HEK293T cells. (a) Acetylation of Polι in 
HEK293T cells transfected with the FLAG-Polι expressing vector and treated, as indicated, with UV-irradiation 
– 7 J/m2, MMS – 1 h, zeocin – 12 hrs, hydrogen peroxide (H2O2) – 1 h, mitomycin C (MMC) – 40 hrs, cisplatin 
(cisPt) – 12 h, or hydroxyurea (HU). 10μg of protein extract was loaded in each line. Polι acetylation was 
visualized by western blot using monoclonal antibodies against acetylated lysines (KAc). Polι was visualized 
using polyclonal rabbit antibodies against a C-terminal fragment of Polι. (b) Acetylation of Polι in HEK293T 
cells transfected with FLAG-Polι plasmid and treated for 1 h with increasing doses of the oxidative agents, 
Hydrogen peroxide (H2O2) or Potassium bromate (KBrO3). (c) Acetylation of Polι in HEK293T cells transfected 
with the FLAG-Polι plasmid and treated for 1 h with alkylating agents, MMS, EMS, MNNG and DMS.
Figure 7. Characterization of Polι K550R and K550Q variants. (a) Effect of the K550R substitution on 
MMS-induced Polι acetylation. Western blot using monoclonal antibodies against acetylated lysines. Polι 
was visualized using polyclonal rabbit antibodies against a C-terminal fragment of Polι. (b) Comparison of 
Polι localization into “replication factories” of wild-type GFP-Polι, GFP-Polι-K550R, and GFP-Polι-K550Q, 
respectively that block, or mimic, acetylation at the K550 residue. Respective plasmids were transfected into 
MRC5 cells. Histogram showing the percentage of nuclei with foci (left panel). Numbers are based upon 3 
replicates where 200 nuclei were counted for each cell line from GFP positive cells. Example of GFP-positive 
cells with a nucleus without foci (right top panel), or with foci (right bottom panel).
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influences enzymatic activities of the polymerase via interactions with other proteins, and this will be a subject 
of future investigation.
The acetylation of Polι in response to MMS treatment was observed without ectopic expression of p300. This 
raised the question of whether p300 itself, or other acetyltransferases modify Polι under alkylating conditions. 
To establish whether p300 acetyltransferase is responsible for the modification, we disrupted the p300 gene in 
a HEK293T cell line using CRISPR-Cas9 technology and assayed the acetylation of Polι in response to MMS 
and DMS in the p300 knock-out cells. To our surprise, in two independently isolated p300 knock-out cell lines 
that were transiently transfected with the FLAG-Polι plasmid, MMS/DMS-induced acetylation of Polι was still 
observable (Fig. 8a), suggesting that p300 is not the only acetyltransferase responsible for Polι’s modification. 
In parallel, we examined Polι acetylation following MMS treatment in cells exposed to the p300 acetyltrans-
ferase inhibitor, L002. HEK293T cells transfected transiently with FLAG-Polι were pre-incubated for 24 hrs with 
DKAc inhibitor and subsequently exposed, or not (controls), to L002. After a 1 hour exposure, cells were treated 
with MMS for an additional one, or two hours. Polι acetylation was assessed in extracts collected at the various 
time points. As shown in Fig. 8b, Polι acetylation is only noticeable in extracts from cells that were not treated 
with p300 inhibitor, strongly suggesting that incubation of cells with L002 effectively prevented Polι acetylation. 
These findings imply that p300 is accountable for Polι acetylation in response to MMS exposure. However, in 
human cells, p300 has a paralogue, CBP, and together they are the only members of one of several classes of 
Figure 8. Characterization of Polι acetylation. (a) Effect of a p300 knock-out on Polι acetylation in cells treated 
for 1 h with 200 μM MMS or DMS. (b) Effect of a p300/CBP inhibitor, L002, on MMS-induced Polι acetylation. 
(c) Immunoprecipitation assay on extracts from HEK293T cells co-transfected with FLAG-Polι and wild-type 
mCBP, or with an L1435A/D1436A (LD) mutation that abolishes acetyltransferase activity of CBP. (d) Effect 
of 1 h treatment with 200 μM MMS, or DMS, on the cellular level of p300 and CBP. (e) Effect of CBP knock-
out on Polι acetylation in cells treated for 1 h with 200 μM MMS or DMS. (f) Effect of p300 overproduction, 
or MMS, or DMS treatment on Polι or Polη acetylation. Immunoprecipitation of FLAG-tagged polymerases 
from extracts from HEK293T cells transfected with FLAG-Polι (left panel) or FLAG- Polη (right panel). As 
indicated, cells were co-transfected with wild-type p300-c-myc, and treated for 1 h with 200 mM DMS, or MMS. 
Unless otherwise stated, HEK293T cells were transiently transfected with the FLAG-Polι plasmid. 24 hrs post 
transfection cells were treated for 24 hrs with DKAc inhibitor cocktail. Proteins were visualized by western 
blot using the following antibodies; polyclonal antibodies against p300 (p300 protein); monoclonal antibodies 
against acetylated lysines (acetylated Polι); polyclonal rabbit antibodies against a C-terminal fragment of Polι; 
or monoclonal antibodies against the FLAG epitope, as indicated.
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acetyltransferase families. It is known that to some extent L002 inhibits CBP acetyltransferase activity and p300 
and CBP often acetylate the same substrates, albeit with different potency16,57. To verify that CBP can acetylate 
Polι, we assayed Polι acetylation in HEK293T cells co-transfected with the plasmid carrying FLAG-tagged Polι 
and a plasmid carrying murine CBP. In the cells treated for 24 hrs with DKAc inhibitor, Polι acetylation was 
clearly observable (Fig. 8c). To further confirm the ability of CBP to acetylate Polι, we assayed cells co-transfected 
with FLAG-tagged Polι and either wild-type CBP, or the inactive L1435A/D1436A mutant58. In cells express-
ing the HAT catalytic dead CBP mutant, Polι was not acetylated, thus confirming that CBP also acetylates Polι 
(Fig. 8c). Finally, we disrupted the CBP gene in a HEK293T cell line using CRISPR-Cas9 technology and verified 
acetylation of Polι in response to MMS and DMS in the CBP knock-out cells (Fig. 8d). Similar to the p300 KO 
cells, acetylation of Polι was still observable. Together, our results suggest that both p300 and CBP acetyltrans-
ferases can acetylate Polι.
As both over-expression of p300/CBP from a plasmid, or MMS/DMS treatment resulted in increased Polι 
acetylation, we decided to check whether treatment with SN2 alkylating agents influences the levels of the p300/
CBP acetyltransferases. In our experiment, we examined the level of native p300 and CBP protein in cells treated 
with MMS, or DMS. It appears that the amount of p300 protein is slightly increased in MMS treated cells and a 
stronger effect is observable in cells treated with DMS. Detection of an augmented amount of acetyltransferase in 
response to those SN2 alkylating agents is clearer in the case of CBP (Fig. 8e).
Finally, our observation that Polι undergoes p300/CBP-dependent acetylation in response to SN2 alkylating 
agents prompted us to determine whether this phenomenon is shared with other Y-family polymerases, particu-
larly with Polη, which is the closest paralogue of Polι in mammalian cells. We investigated acetylation of Polη in 
cells transfected with FLAG-tagged Polη over-expressing p300 or treated with alkylating agents. It appears that 
under the conditions where we observe significant acetylation of Polι there is no acetylation of Polη, suggesting 
that this regulatory mechanism is specific for Polι (Fig. 8f).
Discussion
Polι is a TLS polymerase present in mammals, some other vertebrates and some fungi. The cellular function of 
the enzyme is still far from being understood. Despite the fact that it was identified two decades ago59 and pos-
sesses very peculiar features that are not found in other Y-family DNA polymerases, such as a dRP-lyase activity 
and an extremely high mutagenic potential when copying template T, the cellular function of Polι has yet to be 
determined42,60. In an attempt to decipher the circumstances requiring such an enigmatic enzyme, we investigated 
the mechanism of Polι’s regulation. Polι, like other Y-family polymerases, seems to be primarily controlled by the 
combined action of posttranslational modifications and protein-protein interactions. Similar to other Y-family 
DNA polymerases, Polι is monoubiquitinated in vivo, and so far, it is only known that such a modification facili-
tates its physical and functional interaction with Polη61. Mass spectrometry analysis previously identified over 27 
unique ubiquitination sites in Polι, localized in different functional domains25. Additionally, our earlier studies 
showed that inhibition of p300 acetyltransferase activity induces Polι polyubiquitination31. In the current man-
uscript, we show that Polι not only directly interacts with the p300 acetyltransferase but is subject to acetylation 
itself (Fig. 3). p300 has two enzymatic activities, an acetyltransferase activity, associated with its HAT domain, 
and a ubiquitin ligase activity connected with a non-canonical RING domain15. We explored whether either of 
these domains is located in the region required for an interaction with Polι. Our results revealed that Polι does 
not interact with the N-terminal half of p300 containing the RING domain, but rather with the C-terminal part of 
p300, including the HAT domain (Fig. 1). Although, we cannot formally exclude the possibility that Polι can also 
be ubiquitinated by p300, the lack of an interaction with the N-terminal part of the protein that is required for 
p300 E3 autoubiquitination and E4 polyubiquitination of p53 suggests that p300 ubiquitination of Polι is unlikely.
The main acetylation site of Polι is K550 located in Polι’s Rev1 interacting region (RIR motif 
539-ASRGVLSFFSKKQMQD-554). K550 is a conserved residue found in many different species of mammals, but 
not other vertebrates, which correlates with the conservation of the RIR (Fig. S3). Moreover, K550 is conserved in 
all human and mouse paralogs of Polι, Polη and Polκ62. Nonetheless, we demonstrated that both K550R or K550Q 
mutations, respectively blocking and mimicking acetylation, do not significantly affect the ability of Polι to inter-
act with Rev1. This result is consistent with previous results defining the RIR motif as x-x-x-F-F-y-y-y-y, con-
sisting of two consecutive phenylalanine residues proceeded by no specific residues (x) and followed by any four 
residues (y) excluding proline55. On the other hand, Liu et al., observed significant reduction in the strength of 
the interaction between Rev1 and Polκ when the corresponding lysine in Polκ was mutated to glycine (K571G)63. 
Lysine 550 is located near the interface with Rev1 and can also serve as one of many possible ubiquitination sites25. 
In our previous studies, we speculated that attaching ubiquitin to K550 would obstruct the interaction of Polι and 
Rev125. Following this idea, we can hypothesize that acetylating K550 might prevent its susceptibility to ubiquit-
ination, thereby assuring an opportunity for the two polymerases to interact. In general, the RIRs of TLS DNA 
polymerases play an essential role in regulating TLS activity, however, the interaction between the C-terminal 
domain of Rev1 and RIR motifs of Polη, Polι and Polκ are not exceptionally tight and are often competitive with 
one another. So, it seems that a Rev1-RIR interaction results from a dynamic association, rather than a stable 
connection. Even though the results of our immunoprecipitation experiments show that in general, blocking, or 
mimicking, Polι acetylation does not notably alter the interaction with Rev1, we cannot exclude the possibility 
that it can influence polymerase engagement in the microenvironment of a particular replication block.
To further corroborate the physiological conditions leading to Polι’s modification, we investigated the acetyl-
ation in response to a variety of DNA damaging agents. The results of our experiments showed that Polι is 
acetylated in response to alkylating agents and in much lower extent to oxidative agents (Fig. 6).
It is worth noting that similar to Polι acetylation, Lee et al., observed global acetylation of proteins in cells 
exposed to genotoxic agents, particularly MMS and other alkylating agents and to a lower extent to hydrogen 
peroxide64. However, in contrast to the global protein acetylation that, according to Lee et al., does not depend on 
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p300/CBP, our results show that these two acetyltransferases are responsible for Polι acetylation (Figs 3 and 8). 
Additionally, our results suggest that, at least partially, increased Polι acetylation in response to MMS and DMS 
could be a consequence of higher cellular levels of the two acetyltransferases, as we observed slight induction of 
both p300 and CBP in MMS or DMS treated cells (Fig. 8d). We are unaware of any information in the literature 
reporting the inducibility of p300/CBP in response to DNA damaging agents. However, Cohen et al., showed that 
CBP protein accumulates in the cytoplasm in response to UV radiation65.
Although, our results point to MMS/DMS as the main facilitator of Polι acetylation, we noticed that oxidative 
agents (hydrogen peroxide and potassium bromate) can also induce Polι acetylation (Fig. 6b), but to a much 
lower extent. Since both alkylation and oxidation of DNA, as well as other DNA damaging treatments used in 
this research, can activate the ATR/ATM dependent cascade of kinases governing DNA damage response (DDR), 
one can speculate that Polι acetylation reflects the level of DDR induction. However, based on the literature data 
on phosphorylation of the landmarks of DDR: Chk166, Chk267 or γH2AX68, in response to the DNA damaging 
treatments inducing or not Polι acetylation, we conclude that the Polι acetylation does not correlate with activa-
tion of DDR. While the exact mechanism of how Polι is influenced by the cellular responses is not known, it was 
previously shown that Polι can bypass alkylation or oxidative lesions both in vitro and in vivo32–34,39,69–73.
Both alkylation and oxidative DNA lesions are substrates of base excision repair (BER). It is also worth men-
tioning that Polι displays BER activity in vitro and in vivo and functionally interacts with the BER scaffold protein 
XRCC139,60,74. Furthermore, Polι possesses deoxyribose phosphate (dRP) lyase activity, a feature characteristic 
for BER polymerases58,68. Strikingly, proteins involved in BER represent a significant group among all proteins 
involved in DNA damage response that were found to be acetylated5,75–78. This suggests that protein acetylation 
can considerably influence the activity of BER enzymes, even though it cannot be unequivocally proven that it 
activates or represses BER.
Interestingly, the level of Polι acetylation is particularly high in cells treated with two SN2 alkylating agents: 
MMS and DMS, in contrast to rather moderate acetylation in response to EMS (SN1/SN2) and MNNG (SN1). One 
could speculate that the DNA lesions produced by SN2 rather than SN1 alkylating agents might serve as a signal 
for Polι acetylation. The stronger response to SN2 than SN1 alkylators is intriguing, since the sites methylated in an 
SN2 reaction in duplex DNA are also modified by SN1 alkylating agents. However, in single-stranded DNA, some 
sites are more reactive with MMS than with MNNG79. Accordingly, DNA repair dioxygenases from the AlkB 
family cause resistance to cell killing by SN2 but not the SN1 alkylating agents80–82. On the other hand, SN2 and 
SN1 alkylating agents differently modify amino acids residues83; therefore, at the moment we cannot exclude the 
possibility that Polι acetylation results from SN2 alkylation of proteins, or other cellular constituents. However, 
in light of the known DNA damage tolerance/repair activities of TLS polymerases, the functional connection 
of Polι acetylation with DNA rather than protein modifications by SN2 alkylating agents seems more credible. 
Nonetheless, this phenomenon needs to be investigated in detail and will be the subject of future studies.
Despite the fact that Polι, similar to many other cellular proteins, is acetylated in response to MMS, its closest 
paralogue, Polη, does not follow the same pathway. Additionally, it has been recently shown that Polκ, another 
member of the Y-family DNA polymerases, is not a substrate for in vitro CBP/p300 acetylation22. Polι was thought 
to be a less efficient and more error prone back-up polymerase for Polη31,84. Our results, however, suggest that 
despite many similarities between these two Y-family enzymes, there are cellular requirements and conditions 
devoted specifically for Polι and acetylation of the enzyme might play a role in adjusting its performance to these 
circumstances.
experimental procedures. Reagents- Were purchased from the following vendors: L002, plumbagin, 
MMS, EMS, MNNG, DMS, hydroxyurea, potassium bromate, acetyl coenzyme A, Hoechst from Sigma Aldrich; 
deacetylation inhibitor cocktail from Santa Cruz; zeocin from InvivoGen, MMC and cisplatin from TCI, hydro-
gen peroxide (Chempur), Anti DYKDDDDK Affinity Gel (Biotool), anti HA beads (Life Technologies), DMSO 
(BioShop), Turbofectin 8.0 from Origene, Alexa Fluor 488 Phalloidin (Thermo Fisher Scientific);
Antibodies- anti-FLAG (Abnova, MAB2094), anti-p300 (Santa Cruz, sc-585X and Abcam, ab54984), anti-HA 
(Abcam, ab9110 and Abnova, MAB7911), anti-Polι (Novus Biologicals, NB100-175), anti-N-terminal Polι and 
anti-C-terminal Polι7, anti-acetylated lysine (Thermo Scientific, MA1-2021), anti-CBP (Bethyl Laboratories, 
PLA0097 and Santa Cruz, sc-730), anti-tubulin (Abcam, ab 6160).
Plasmids. Vectors expressing truncated or mutated variants of Polι (pJRM258 – pJRM262) were generated by 
sub-cloning respective PCR fragments into pJRM4661 expressing N-terminal FLAG-tagged full-length human 
Polι. Plasmids pJRM264, pDH77, pGS11, pGS7 and pNWA10 are pJRM46 derivatives with single, or double 
lysine to arginine, lysine to glutamine or lysine to alanine substitutions that were generated by chemically synthe-
sizing appropriate DNA fragments (Genscript) and subsequently sub-cloned into pJRM46. Vectors pJRM242 and 
pJRM244, expressing N- or C-terminal fragments of p300 proteins tagged with an HA-epitope, were generated 
by sub-cloning respective PCR fragments into the pCMV6AN-HA vector (Origene). Plasmid pGS23, express-
ing full-length wild-type human Rev1 was generated by sub-cloning the codon optimized synthesized REV1L 
gene (Genscript) into pCMV6AN-HA. Plasmids pGS24 and pGS25 expressing eGFP-tagged full-length Polι with 
single K550R, or K550Q mutations, respectively, were generated by chemically synthesizing appropriate DNA 
fragments (Genscript) and their subsequent sub-cloning into pDH2485. The full list of all the plasmids used in 
this study is shown in Table 1.
Plasmid Transfection and Protein Expression. In all of our experiments, we have used ectopically expressed Polι, 
because the endogenous level of Polι in HEK293T cells is very low86.
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Mammalian expressing constructs were transfected into HEK293T cells using Turbofectin 8.0 according to 
manufacturer’s instructions (Origene). Twenty-four to forty-eight hours post transfection cells were harvested 
and lysed. The presence of expressed proteins of interest was verified by western blot.
Human p300 and CBP Knock-out by CRISPR/Cas9. A p300 knock-out in a HEK293T cell line was gen-
erated using the p300CRISPR/Cas9 KO and p300HDR plasmids purchased from Santa Cruz (sc-400055 and 
sc-400055-HDR, respectively). A CBP knock-out in the HEK293T cell line was performed using CBP CRISPR/
Cas9 KO and CBP HDR plasmids purchased from Santa Cruz (sc-400200 and sc-400200-HDR, respectively). 
The knock-out procedure was performed according to the manufacturer’s recommendations. Briefly, HEK293T 
cells were co-transfected with p300CRISPR/Cas9 KO and p300HDR or CBP CRISPR/Cas9 KO and CBP HDR 
plasmids and the successful co-transfections were visually confirmed by detection of the green fluorescent pro-
tein (GFP) and red fluorescent protein (RFP) via fluorescent microscopy. 48 hrs post transfection the media was 
removed and replaced with one containing puromycin and cells were selected on the medium with the antibiotic 
for another 5 days with fresh media replacement every 2 days. Next, single cell colonies were isolated and com-
plete knockouts were confirmed by western blot with antibodies against p300 or CBP.
Foci Formation of DNA Polι. The GFP- Polι foci formation assay was performed as described previously86. 
Briefly, the eGFP constructs were transfected into MRC5 fibroblasts previously plated onto coverslips. 
Twenty-four hours after transfection, cells were fixed using 3.7% formaldehyde in PBS and mounted onto slides 
using Mowiol mounting medium. Fluorescence images of cell nuclei were acquired on a Zeiss Axiovert 40 
CFL (Carl Zeiss) with X-cite Series 120Q light source, using Zen 2 (blue edition) software. A minimum of 200 
GFP-expressing nuclei, were analyzed for each cell line per line.
Immunoprecipitation Assay. For the immunoprecipitation assay of acetylated Polι and Polη, respective cell 
extracts including FLAG-tagged proteins were incubated for one hour to overnight at 4 °C with Anti-DYDDDDK 
(Flag) Affinity Gel (Biotool), washed three times and analyzed directly by SDS-PAGE and western blot. For the 
immunoprecipitation assay regarding Polι interaction, respective cell extracts including FLAG- or HA-proteins 
were incubated for one hour at 4 °C with Anti-DYDDDDK (Flag) Affinity Gel (Biotool), or Pierce HA Epitope Tag 
Antibody Agarose (Thermo Scientific) respectively. Post incubation resins were washed five times and analyzed 
directly by SDS-PAGE and western blot.
Proximity Ligation Assay (PLA). Prior to the proximity ligation assay (PLA), MRC5 fibroblasts were cultured 
and fixed on slides with 4% paraformaldehyde and 4% sucrose in PBS for 10 min at room temperature. After 
fixation, the cells were rinsed with PBS then incubated overnight at 4 °C with primary antibodies for Polι and 
p300 diluted 1:250 in 1% donkey serum (DS) and 0.2% Triton X-100 in PBS. The proximity ligation assay (PLA; 
Plasmid Description Source/Ref.
pJRM46 pCMV6AN-DDK-polι 1-715aa 61
pJRM258 pCMV6AN-DDK-polι 1-419aa this work
pJRM259 pCMV6AN-DDK-polι 1-470aa this work
pJRM260 pCMV6AN-DDK-polι 1-537aa this work
pJRM261 pCMV6AN-DDK-polι 1-676aa this work
pJRM262 pCMV6AN-DDK-polι 409-715aa this work
pJRM264 pCMV6AN-DDK-polι K550R this work
pDH77 pCMV6AN-DDK-polι K550Q Woodgate lab
pGS7 pCMV6AN-DDK-polι K549R/K550R this work
pGS8 pCMV6AN-DDK-polι K549Q/K550Q this work
pNWA10 pCMV6AN-DDK-polι  F546A/F547A Woodgate lab
pJRM160 pCMV6AN-DDK-polη this work
pDH24 peGFP-Polι 89
pGS24 peGFP-Polι K550R this work
pGS25 peGFP-Polι K550Q this work
pCMVβ-p300-myc gift from Tso-Pang Yao (Addgene # 30489)
pCMVβ-p300.DY-myc gift from Tso-Pang Yao (Addgene # 30489)
pJRM242 pCMV6AN-DDK-p300ΔC this work
pJRM244 pCMV6AN-DDK-p300ΔN this work
pcDNA3β-FLAG-CBP-HA 58
pcDNA3β-FLAG-CBP-LD-HA 58
pGS23 pCMV6AN-HA-Hs_CO-FL-Rev1 this work
pJM868 His-Ec-CO-polι_wt 87
Table 1. Plasmids used in this study.
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Sigma DUO92004-100RXN) was performed using 40 μL of reaction per slide according to the manufacturer’s 
instruction. In brief, slides after overnight incubation with primary antibodies recognizing Polι and p300 were 
washed with PBS (3x) and incubated with two PLA secondary antibodies with probes, anti-mouse MINUS and 
anti-rabbit PLUS for 1 hour at 37 °C. Slides were then washed with buffer A, followed by the ligation reaction, for 
30 min at 37 °C. Subsequently the amplification reaction was performed for 100 min at 37 °C, followed by washing 
with buffer B (all ingredients and buffers were provided by manufacturer) and mounting with VECTASHIELD 
Mounting Medium with DAPI for nucleus visualization. Images of immunofluorescently stained cells were 
acquired using confocal microscopy. The confocal system consisted of a Zeiss LSM800 Exciter microscope 
equipped with lasers that produced light at 405, 488, and 594 nm wavelengths was used for the acquisition of 
pictures of PLA positive cells, 40×/1.30 objective was used to scan samples. A series of continuous optical sec-
tions at 0.4 µm intervals along the z-axis of a cell were scanned for all fluorescent signals and stored as a series of 
1024 × 1024 pixel images. The laser power and image acquisition settings were kept constant.
Protein Purification. Full-length recombinant human Polι was purified as described previously87. Briefly, 
pJM868 plasmid encoding His-tagged Escherichia coli-codon optimized human Polι87 was expressed in the E. coli 
strain RW64488. The His-Polι protein was purified on HisPur Ni-NTA Superflow Agarose (Thermo Scientific) as 
recommended by the manufacturer. The eluate containing Polι was dialyzed in buffer including 20 mM sodium 
phosphate pH 7.3, 10 mM sodium chloride, 10% glycerol, 10 mM 2-mercaptoethanol, and applied to HP Q 
Sepharose (GE Healthcare). Polι was eluted in a step gradient of sodium chloride. Full-length recombinant p300 
was purchased from Active Motif.
Mass Spectrometry. LC-MS analysis of gel slices was conducted in Mass Spectrometry Lab, Institute of 
Biochemistry and Biophysics, Polish Academy of Science, where they were analyzed by mass spectrometry as a 
custom contract service.
In vitro Acetylation. Acetylation reactions were performed in acetylation buffer (50 mM Tris pH8, 150 mM 
sodium chloride, 1 mM DTT, 10 mM sodium butyrate, 5% glycerol) with the addition of 100 μM acetyl coenzyme 
A, 1 mM PMSF, 100 ng of p300 (Active Motif) and purified recombinant Polι for 1 hour at 30 °C. The reaction was 
then stopped by the addition of Laemmli buffer and followed by SDS-PAGE.
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